Abstract: Adequate control of lipids is a cornerstone in the management of coronary heart disease. Numerous studies have demonstrated the effectiveness of HMG-Co A reductase inhibitors (statins) in controlling LDL-C. Unfortunately, the effect of statins on other lipid parameters, such as HDL-C and triglycerides, is not as robust. Emerging evidence suggests that these other lipid parameters may contributetoresidualcardiovascularrisk.Therecentreleaseoffenofibricacidoffersapotentialtherapywhichcanbeusedin conjunction withstatinstoachieveanoptimallipidprofile.Clinicaltrialshavedemonstratedfenofibricacidtobesafeforuseasdualtherapywith lowandmoderatedosestatins.Thefollowingarticlewilladdressthesafetyandefficacyoffenofibricacidinthetreatmentoflipiddisorders,bothaloneandascombinationtherapywithstatins.Additionally,thepotentialroleoffenofibricacidinthemanagementofthe complexcardiovascularpatientwithabnormallipidparameterswillbeevaluated.
Introduction
Treatment of abnormal lipid parameters is critical to maintaining cardiovascular health. The benefits of adequate treatment of LDL-C with HMG Co-A reductase inhibitor (statin) therapy for both primary and secondary prevention are well documented.
1,2
Clearly, however, adverse cardiovascular outcomes arenoteradicatedwithstatintherapy.Majoradverse cardiac events can persist despite treatment of LDL-C to goal and other important lifestyle modifications. There is emerging evidence that some of this residual risk may be due to other abnormal lipid parameters, such as elevated triglycerides and decreased HDL-C. [3] [4] [5] [6] [7] [8] [9] Taken together, the constellation of these twofindingsalongwithelevatedLDL-Crepresentsa highly atherogenic form of dyslipidemia. Treatment options to address these factors have been limited in the past by untoward side effects and safety issues. 10 Recently, a new formulation of fenofibrate hasbecomeavailable.Fenofibricacidisacholinesalt of fenofibrate which shows promising results and a favorablesafetyprofilewhenadministeredwithlow and moderate dose statin therapy. 11, 12 Pharmacodynamics Fenofibricacidisaperoxisomeproliferatoractivated receptor (PPAR) alpha agonist. PPAR alpha is a nuclear transcriptionfactorfoundintissueswithhighratesof fattyacidcatabolismwhichhelpsregulatethegenes involved in fatty acid and triglyceride metabolism. 13 Specifically, it controlsfattyaciduptakeandesterification and promotes the beta-oxidative degradation of fatty acids. In addition, PPAR alpha has been showntodisplaysomeanti-inflammatoryproperties, including reduction of cytokine-induced vascular cell adhesion moelecule-1 (VCAM-1) and endothelin-1 (ET-1), a potent vasoconstrictor.
14 Fibrates are synthetic ligands for PPAR alpha and as such, both stimulate lipoprotein lipase production and decrease apo C-IIIexpression,whichisaninhibitoroflipoprotein lipase. The resulting increase in lipoprotein lipase improves fatty acid uptake and decreases fatty acid production. By decreasing triglycerides, LDL particle number is effectively decreased and LDL particle size is increased. Additionally, they contribute to increased HDL-C levels by stimulating production of apo A-I and A-II.
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Pharmacokinetics
Fenofibric acid differs from its predecessor, fenofibrate, primarily by demonstrating improved bioavailablity.Fenofibrateispoorlysolubleinwater and highly lipophilic. 18 These properties result in slow and unpredictable dissolution in the GI tract, limitingitsabsorption.Incontrast,fenofibricacidhas highwatersolubilityandnearcompletedissolutionin the GI tract. 19 Absolute absorption in the GI tract has beenreportedat81%forfenofibricacidversus69% for fenofibrate. 20 Peak plasma levels are achieved withinfourtofivehours,irrespectiveoffastingstatus.Concomitantusewithbileacidsequestrantsmay decrease absorption. It is therefore recommended that fenofibric acid be taken at least one hour before or four to six hours after a bile acid sequestrant. Fenofibricacidisexcretedprimarilyintheurineandmay accumulate in patients with severe kidney disease. It is metabolized through CYP3A4 and is therefore pronetointeractionwithothermedicationsusingthis pathway.Increasednephrotoxicityandrhabdomyolysishavebeenreportedwhenusedwithcyclosporine. Fenofibricacidishighlyproteinboundandprudent usewithwarfarinisadvised,asfenofibricacidmay prolong the prothrombin time. 15 Unlike its predecessor,gemfibrozil,fenofibricaciddoesnotsignificantly interactwithstatins.Earlyfibrateformulationsinhibited the biliary secretion and glucuronidation of statins whichresultedinincreasedlevelsandtoxicity.
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Clinical Trials
Threerandomizedtrialshaveevaluatedfenofibricacid incombinationwithstatintherapyandhavefoundthe combinationoffenofibricacidwithlowandmoderate dose statin to be safe and effective. [23] [24] [25] All three trialsstudiedfenofibricacidatadoseof135mg/day. Patientswererandomizedtoeithermonotherapywith low,moderateorhighdosestatinortocombination therapy with fenofibric acid and low or moderate dosestatin.Eachofthethreetrialsevaluatedfenofibricacidwithadistinctstatin.Thethreestatinsevaluatedwererosuvastatin,simvastatinandatorvastatin. Enrolled patients had mixed dyslipidemia at baseline. Changes in fasting cholesterol, apolipoprotein B and hsCRP were compared at baseline and throughout thetrialsuptotwelveweeks.Thethreetrialsdemonstrated consistent improvements in lipid parameters andanencouragingsafetyprofileinthecombination therapy arms. (see Tables 1, 2 and 3) . In general, the highest treatment related adverse event rate and the highest dropout rate occurred in the high dose statin monotherapy arms.A 52-week extension trial combined the patients in these trials in a study to examine the long term safety and efficacy of fenofibric acid withmoderatedosestatintherapy.
11 Improvement in lipid profiles was seen by four weeks of dual therapyandwassustainedthroughoutthe52-weektrial. Decreases in other lipid parameters, including non-HDL-C, total cholesterol and apo lipoprotein B levels,werealsoseen.Apositivesafetyprofilepersisted throughout the extension study. Only eight patients out of2201hadmajortreatmentrelatedadverseevents. These typically involved cholecystitis, choletlithiasis and abdominal pain. Elevated liver function test or CPKwereseeninonly1%ofpatients.Nocasesof rhabdomyolysiswereobserved.
A post-hoc analysis of the three 12-week trials was performed to determine any effects fenofibric acidtherapyeitheraloneorincombinationwithstatin therapy had on the prevalence of Metabolic Syndrome or its diagnostic components. 26 At baseline, data was available for all five metabolic syndrome criteriainthemajorityofpatients.Diagnosticcriteria forthediagnosisofmetabolicsyndromewaspresent in82.5%ofpatientsuponenrollment.Patientswere reassessedattheendof12weeksfordiagnosticcri-teria for metabolic syndrome. Combination therapy with fenofibric acidwithlow ormoderatedosestatin therapy decreased the number of patients meeting diagnostic criteria for the metabolic syndrome by nearly 36% when compared with statin monotherapy. Additionally, fenofibric acid monotherapy reduced those meeting diagnostic criteria by 26%.
Predictably, dual therapy had the largest impact in decreasing the number of patients meeting the specific criteria of hypertriglyceridemia and decreased HDL-C, although small improvements in blood pressureandfastingbloodglucosewerealsoseen.
Safety Profile
The previously mentioned studies have resulted in fenofibric acid becoming the sole fibrate FDA approvedforusewithlowandmoderatestatinsinthe treatment of patients with mixed dyslipidemia and CHD. 15 Historically,thecombinationoffibratesand statins has been avoided due to safety concerns. 16, 27 One of the original fibrate medications, gemfibrozil,wasfoundtoinhibitglucuronidationandthereby decrease the elimination of statins, resulting in increased toxicity.Thesecondgenerationfenofibrate isamuchweakerinhibitorofglucuronidation,resulting in fewer reports of toxicity.
28 Fenofibric acid's safetyprofilewithlowandmoderatedosestatintherapy is well documented. Myalgias were reported in 3.3%ofpatientsonfenofibricacidmonotherapyand 3.1and3.5%inpatientsonlowandmoderatedose dual statin therapy, respectively. Myalgias occurred in4.7and6.1%ofpatientsonlowandmoderatedose statin monotherapy.
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No significant effect on liver function tests or CPK levels have been noted. The number of patients developing an increase in CPK to greater than five times normal on dual therapy was lowanddidnotdifferbetweendualtherapygroups and statin monotherapy groups. No patients receivingfenofibricacidmonotherapyreportedanincrease inCPKtogreaterthanfivetimesnormal.
11,26 A small trial evaluating potential interactions of fenofibric acid with 40 mg of rosuvastatin did not reveal significant interaction with high dose statin therapy in Table 1 . Simvastatin monotherapy effect on LDL was not evaluated in the study. Fenofibric acid monotherapy effect on HDL and triglycerides was not evaluated in the study. healthy young volunteers. 29 However, the combination of high dose statin and fenofibric acid has not adequately been evaluated and should be avoided.
Mean % change
Common adverse effects are nausea, myalgia, headache and back pain. These rarely result in medication discontinuationhowever.Theriskofrhabdomyolysis hasbeenshowntobeverylow,andequaltothatof statin monotherapy. By increasing cholesterol excretionintobile,fibratespotentiatecholelithiasis.
Dosing
InadditiontoitsFDAapprovalforusewithlowand moderate dose statin therapy, it is approved as monotherapy for severe hypertriglyceridemia and mixed dyslipidemia. The adult starting dose in combination withstatintherapyormonotherapyforprimaryhyperlipidemia or mixed dyslipidemia is 135 mg once daily and may be taken at the same time as statin therapy. For the treatment of severe hypertriglyceridemia, the starting dose is 45 to 135 mg once daily and may beadjustedat4-8weekintervalstoamaximumof 135 mg daily. 15 Patientswithmildtomoderaterenal impairment (creatinine clearance 30-80 ml/min) should be started at 45 mg once daily and be closely monitored.Fenofibricacidiscontraindicatedinthose with severe renal impairment (including those on dialysis),thosewithactiveliverdisease,preexisting gallbladder disease and nursing mothers.
Effectiveness
Fenofibricacidispotentinimprovingtriglycerideand HDL-Clevels,bothaloneandincombinationwithlow and moderate dose statin therapy. With monotherapy, fenofibricacidhasbeenshowntoresultina16.3% increase in HDL-C.
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One study showed a greater increase in HDL-C levels compared to prior studies of fenofibrate.
24 Dualtherapywithstatinsresultedinan 18%increaseinHDL-C. Triglycerideswerereduced approximately31%with monotherapyand42%-43% with combination therapy. Combination therapy resultedinmoreofadecreaseinVLDLwhencomparedtofenofibricacidorstatinmonotherapy.While thecombinationoffenofibricacidwithlowormoderate dose statin improved non-HDL and apoB levels, the effect was not significantly higher than that achievedwithstatinmonotherapy.
Place in Therapy
Fenofibricacidoffersseveralappealingcharacteristics that make it an attractive therapy in the treatment of Table 2 . Rosuvastatin monotherapy effect on LDL was not evaluated in the study. Fenofibric acid monotherapy effect on HDL and triglycerides was not evaluated in the study. Table 3 . Atorvastatin monotherapy effect on LDL was not evaluated in the study. Fenofibric acid monotherapy effect on HDL and triglycerides was not evaluated in the study. lipiddisorders.Itcanbetakenoncedailyandwithout consideration to oral intake.There are relatively few interactionswithothercommonlyprescribeddrugs,and itssafetywithlowandmoderatedosestatintherapyis wellestablished.Thereiscurrentlyacombinationpill withrosuvastatinindevelopmentwhichmayimprove compliance in patients in need of dual therapy. Whilefenofibricacidclearlyprovidesan additional and favorable option in the treatment of lipid disorders, it is important to acknowledge that studies are lackingwhichdemonstateamorbidityormortalitybenefit. This is in contrast to the numerous studies demonstratingsuchbenefitwithstatintherapy.However,onein fivepatientswhoareatgoalLDLwithstatintherapy continue to have events. 30 The underlying causes of this residual risk are not clearly delineated, although previous studies provide clues that lipid parameters beyond LDL may play an important role. Statin trial meta-analyses have shown the highest placebo event rate and greatest absolute reduction in clinical events inpatientswiththelowestbaselineHDL-C.
Mean % change
31,32
Low HDL-C is also the most common lipid abnormality in patients with premature CAD. Prior trials with older fibratemedicationssuggesttheimportanceoftreating low HDL-C and elevated triglycerides. The VA-HIT trialfoundthatgemfibrozilreducedmortalityandnon fatal MI independent of changes in LDL-C. 33, 34 The BECAIT trial found a decrease in disease progression whenHDLandtriglycerideprofilesimproveddespite no change in LDL-C. 35 TreatingtoNewTargetsestablishedthatpatientswithlowHDL-C(,42mg/dl)hada highereventrateevenwhenLDL-Cwas,70mg/dl. 36 A secondary prevention trial in patients with acute coronary syndrome, PROVE-IT 22, found the best outcomesoccurredwhenLDL-Cwas,70mg/dland triglycerides were ,150 mg/dl. 37 A recent meta-analyses oftrialswhichusedIVUStomonitorplaqueprogression determined that progressors had higher levels of triglycerides, glucose, apoB and smaller increases in HDL-Cwhencomparedtonon-progressors.
38
Recent studies evaluating the use of fibrates to improve residual risk have had disappointing results. The FIELD study evaluated the effect of fenofibrate on CV outcomes in patients with type 2 diabetes mellitus. 39 The primary outcome of major coronary events was not reduced. Slight reductions incoronaryrevascularizationandnon-fatalMIwere noted. Microvascular complications of DM, such as albuminuria and need for laser retinopathy, were reduced. The ACCORD lipid study randomized type 2diabeticpatientstosimvastatinplusfenofibrateor placebo. 40 The primary outcome was first non-fatal MI or CVA or death from CV cause. Combination therapy was not found to reduce the event rate for primary outcomes, and the routine use of dual therapy wasnotrecommended.Whilethesetrialssuggestthat fibrates do not contribute to reducing residual risk, they do not sufficiently address the question. The largest criticism of these trials was that the patient population did not adequately represent those who arecommonlytargetedinclinicalpracticeforfibrate therapyeitheraloneorincombinationwithstatin.
41
TheFIELDstudyincludedpatientswithnormallipids and had a high drop in rate of statins. In the ACCORD lipid study, the baseline triglyceride level was 162mg/dLandbaselineHDLwas38.1mg/dL.While these levelsarenotquiteatgoal,theydonotreflect the patient seen in clinical practice that is considered for dual therapy. Importantly, a subgroup analysis of theACCORD lipid study found that fibrate therapy diddecreasetheeventrateinpatientswithtriglycerides .204mg/dLandHDL-C<34mg/dL.
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Conclusion
While clinical trials are ongoing, substantial evidence existswhichsuggestsanimportantroleforfenofibric acid in the treatment of dyslipidemia, hypertriglyceridemiaandhyperlipidemia.Studiesoffenofibricacid consistentlydemonstrateanimpressivesafetyprofile, eveninconjunctionwithstatintherapy.Theimproved bioavailabilitycomparedtopriorfibrateformulations isanadditionalbenefit.Theeffectsonlipid parameters are notable, especially the pronounced decrease in triglyceride levels which can be achieved with dual therapywithstatins.Furthertrialswithanappropriate patientpopulationwhichreflectsthoseseeninclinical practice that are most commonly targeted for dual therapy with a statin could potentially demonstrate thesoughtaftermorbidityandmortalitybenefitsthat iscurrentlylackingforfibrates.
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